Navigation Links
BioMed Realty Trust Reports Third Quarter 2007 Financial Results
Date:11/7/2007

Add:

Minority interest $0.03

Real estate depreciation and amortization $1.16

Projected FFO per diluted share $1.86 - 1.96

Consistent with the 2007 guidance, the company's 2008 guidance does not include the impact of future acquisition activities. In addition, the company's 2008 guidance does not include any expected lease termination income.

The foregoing estimates are forward-looking and reflect management's view of current and future market conditions, including certain assumptions with respect to leasing activity, rental rates, occupancy levels, interest rates, and the amount and timing of development and redevelopment activities. The company's actual results may differ materially from these estimates.

Supplemental Information

Supplemental operating and financial data are available in the Investor Relations section of the company's web site at http://www.biomedrealty.com.

Teleconference and Web Cast

BioMed Realty Trust will conduct a conference call and audio web cast at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) Thursday, November 8, 2007 to discuss the company's financial results and operations for the quarter. The call will be open to all interested investors either through a live audio web cast at the Investor Relations section of the company's web site at http://www.biomedrealty.com and http://www.earnings.com, or live by calling (866) 770-7125 (domestic) or (617) 213-8066 (international) with call ID number 10729297. The call will be archived for 30 days on both web sites. A telephone playback of the conference call will also be available from 3:00 p.m. Pacific Time on Thursday, November 8, 2007 through midnight Pacific Time on Tuesday,
'/>"/>

SOURCE BioMed Realty Trust, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
2. Biomedtex Inc. Announces A. Marc Rocca as President and CEO
3. Hopes, Predictions and Realities: Is Biomedical Research Delivering On Its Promises?
4. Dr. Andrew K. Palmer Joins BMEs (BioMedical Enterprises, Inc.) Board of Directors
5. BioMed Realty Trust to Report 2007 Third Quarter Results
6. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant
7. Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange
8. Universal Health Realty Income Trust Announces Dividend
9. Healthcare Realty Trust Announces Public Offering of Common Stock
10. New Poll Shows Public Distrusts Flawed Healthcare Approach Favored by Governor and Speaker in AB 8
11. AUDIO from Medialink and Allergan: Women Not Sure Who to Trust on Anti-Aging Skin Care
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:NutraCea Announces Third Quarter 2008 Financial Results 2Health News:NutraCea Announces Third Quarter 2008 Financial Results 3Health News:NutraCea Announces Third Quarter 2008 Financial Results 4Health News:NutraCea Announces Third Quarter 2008 Financial Results 5Health News:NutraCea Announces Third Quarter 2008 Financial Results 6Health News:NutraCea Announces Third Quarter 2008 Financial Results 7Health News:NutraCea Announces Third Quarter 2008 Financial Results 8Health News:NutraCea Announces Third Quarter 2008 Financial Results 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 14Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 15Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 16Health News:Misys Wins 'Best Trade Processing Product' Accolade in European Banking Technology Readers' Choice Awards 2Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 2Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 3Health News:Dr. Tiffany McCormack in Reno, Nevada Named in Forbes Magazine as One of 10 Most Dependable Plastic Surgeons in the West 4Health News:More People Living Longer After Cancer Diagnosis 2Health News:Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education 2Health News:Zimmer Holdings to Collaborate with the American Orthopaedic Association for Funding Post-Graduate Medical Education 3
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 1Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 2Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 3Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 4Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 5StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 1StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 2StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 3StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 4National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 1National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 2National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 3National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 4